No two days are the same for the managing partner of 5 AM Ventures, Dr. Scott Rocklage. Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from the Massachusetts Institute of Technology (MIT) where he conducted research under Richard R. Schrock’s (Nobel Prize in Chemistry in 2005) laboratory. Dr. Scott Rocklage has three decades of healthcare management experience, three FDA-approved drugs, 30 patents, and 100 peer-reviewed publications, as well as the backing of 5 AM Ventures, Dr. Rocklage is at the forefront of innovation. Under Scott’s leadership, 5 AM Ventures was able to raise $285 million in 2016 to bring the firm’s total raised capital to $1 billion, facilitate the acquisition or IPO of 14 companies and lead various companies to exits in the marketplace and more information click here.
Dr. Scott Rocklage has previously served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar, and various research and development positions at Salutar and Catalytica. He has served as the former board chairman of Relypsa (NASDAQ: RLYP), Novira(acquired by Johnson & Johnson), Ilypsa (acquired by Amgen, Miikana (acquired by EntreMed), and Semprus (acquired by Teleflex). He currently serves as the chairman of Rennovia, Kinestral, Cidara (NASDAQ: CDTX), Epirus(NASDAQ: EPRS), Pulmatrix (NASDAQ: PULM). No one can parallel Dr. Rocklage’s experience and knowledge in the seed, early-stage, growth capital, startup investments, and spinouts market for drug development, biopharmaceuticals, biotechnology, product discovery platforms, research instrument sectors and medical technologies field. Seeing the many achievements and positions of Dr. Rocklage, it is easy to see why no two days are the same and resume him.
More visit: https://ideamensch.com/scott-rocklage/